Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.70 |
| ▸ | ITGAV | P06756 | 20/20 | 0.70 |
| ▸ | ITGA2B | P08514 | 20/20 | 0.70 |
| ▸ | ITGB6 | P18564 | 9/20 | 0.68 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.68 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8325196 | 0.96 | ITGB3 (0.76) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL2839348 | 0.93 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL2839393 | 0.92 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL2833708 | 0.92 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL2839415 | 0.91 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL2836389 | 0.91 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL2836326 | 0.90 | ITGB3 (0.69) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL5858263 | 0.90 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL8336940 | 0.89 | ITGB3 (0.78) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL2834556 | 0.89 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB6ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | claimed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | claimed |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | ITGB3 6/4885ITGAV 2/4885ITGA2B 8/4885 |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGA2B 4/4885 |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGA2B 4/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.